Abstract:OBJECTIVE:IL-35 (interleukin-35) is an anti-inflammatory cytokine, which inhibits immune responses by inducing regulatory T cells and regulatory B cells and suppressing effector T cells and macrophages. It remains unknown whether atherogenic stimuli induce IL-35 and whether IL-35 inhibits atherogenic lipid-induced endothelial cell (EC) activation and atherosclerosis. EC activation induced by hyperlipidemia stimuli, including lysophosphatidylcholine is considered as an initiation step for monocyte recruitment and atherosclerosis. In this study, we examined the expression of IL-35 during early atherosclerosis and the roles and mechanisms of IL-35 in suppressing lysophosphatidylcholine-induced EC activation.APPROACH AND RESULTS:Using microarray and ELISA, we found that IL-35 and its receptor are significantly induced during early atherosclerosis in the aortas and plasma of ApoE (apolipoprotein E) knockout mice-an atherosclerotic mouse model-and in the plasma of hypercholesterolemic patients. In addition, we found that IL-35 suppresses lysophosphatidylcholine-induced monocyte adhesion to human aortic ECs. Furthermore, our RNA-sequencing analysis shows that IL-35 selectively inhibits lysophosphatidylcholine-induced EC activation-related genes, such as ICAM-1 (intercellular adhesion molecule-1). Mechanistically, using flow cytometry, mass spectrometry, electron spin resonance analyses, and chromatin immunoprecipitation-sequencing analyses, we found that IL-35 blocks lysophosphatidylcholine-induced mitochondrial reactive oxygen species, which are required for the induction of site-specific H3K14 (histone 3 lysine 14) acetylation, increased binding of proinflammatory transcription factor AP-1 in the promoter of ICAM-1, and induction of ICAM-1 transcription in human aortic EC. Finally, IL-35 cytokine therapy suppresses atherosclerotic lesion development in ApoE knockout mice.CONCLUSIONS:IL-35 is induced during atherosclerosis development and inhibits mitochondrial reactive oxygen species-H3K14 acetylation-AP-1-mediated EC activation.

Interleukin-12p35 Deficiency Reverses the Th1/Th2 Imbalance, Aggravates the Th17/Treg Imbalance, and Ameliorates Atherosclerosis in ApoE-/- Mice

IL-35 promotes CD4<SUP>+</SUP>Foxp3<SUP>+</SUP> Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms

The Modulation of Endoplasmic Reticulum Stress by Chemical Chaperone Upregulates Immune Negative Cytokine IL-35 in Apolipoprotein E-Deficient Mice

IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms

Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice Through Regulatory T Cell Augmentation and Dendritic Cell Tolerance.

The Th17/Treg Functional Imbalance During Atherogenesis in ApoE(-/-) Mice.

Abstract 029: Interleukin-35 Suppresses Endothelial Activation by Inhibiting Mitochondrial Reactive Oxygen Species Mediated Site-specific Acetylation of Histone 3 Lysine 14

Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice

Interleukin-17-Producing CD4+ T Cells Promote Inflammatory Response and Foster Disease Progression in Hyperlipidemic Patients and Atherosclerotic Mice

IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (histone 3 Lysine 14).

Association Between Type I Interferon and Depletion and Dysfunction of Endothelial Progenitor Cells in C57BL/6 Mice Deficient in Both Apolipoprotein E and Fas Ligand.

Abstract 211: IL-35 Suppresses Endothelial Cell Activation by Inhibiting Histone H3K14 Acetylation and AP-1

Inhibition of IL-17A in Atherosclerosis

Interleukin-25 (IL-25) has a protective role in atherosclerosis development in the aortic arch in mice

IL-12p40 deletion reduces M1 macrophage polarization and alleviates cardiac remodeling via regulating Th17 cells differentiation, but not γδT 17 cells, in TAC mice

Interleukin 35 Induced Th2 and Tregs Bias under Normal Conditions in Mice

Interleukin-17A Influences the Vulnerability Rather Than the Size of Established Atherosclerotic Plaques in Apolipoprotein E-deficient Mice

TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.

IL-12R2 Promotes the Development of CD4CD25 Regulatory T Cells1

IL-9 Aggravates the Development of Atherosclerosis in ApoE-/- Mice.

A Critical Function of Th17 Proinflammatory Cells in the Development of Atherosclerotic Plaque in Mice